抗逆转录病毒联合治疗停止后，核苷类逆转录酶抑制剂、非核苷类逆转录酶抑制剂和蛋白酶抑制剂相关耐药突变动态的比较。
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
作者信息
Wirden Marc, Delaugerre Constance, Marcelin Anne Genevieve, Ktorza Nadine, Ait Mohand Hocine, Dominguez Stephanie, Schneider Luminita, Ghosn Jade, Pauchard Michele, Costagliola Dominique, Katlama Christine, Calvez Vincent
机构信息
Department of Virology, INSERM EMI 0214, Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004.
Abstract
The dynamics of mutations associated with resistance to antiretroviral drugs were analyzed after cessation of therapy. The results showed that the kinetics of the shift to wild-type amino acid residues were significantly faster for protease inhibitors, intermediate for nonnucleoside reverse transcriptase inhibitors, and slower for nucleoside reverse transcriptase inhibitors.
摘要
在停止治疗后，分析了与抗逆转录病毒药物耐药性相关的突变动态。结果显示，向野生型氨基酸残基转变的动力学对于蛋白酶抑制剂而言显著更快，对于非核苷类逆转录酶抑制剂而言处于中等水平，而对于核苷类逆转录酶抑制剂而言则较慢。
相似文献
1
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004.
2
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
PLoS Med. 2006 Sep;3(9):e356. doi: 10.1371/journal.pmed.0030356.
3
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
AIDS. 2009 Jul 31;23(12):1605-8. doi: 10.1097/QAD.0b013e32832d9031.
4
[Evolution of HIV resistance mutations in the Valme referral center].
Enferm Infecc Microbiol Clin. 2007 Feb;25(2):159. doi: 10.1016/s0213-005x(07)74247-7.
5
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Antimicrob Agents Chemother. 2009 May;53(5):2196-8. doi: 10.1128/AAC.01593-08. Epub 2009 Feb 17.
6
Changes in the rate of genotypic resistance to antiretroviral drugs in Spain.
AIDS. 2001 Sep 28;15(14):1894-6. doi: 10.1097/00002030-200109280-00025.
7
Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
AIDS. 2019 May 1;33(6):1073-1082. doi: 10.1097/QAD.0000000000002166.
8
HIV-1 drug resistance in newly infected individuals.
JAMA. 1999;282(12):1135-41. doi: 10.1001/jama.282.12.1135.
9
Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
J Infect Dis. 1999 Aug;180(2):568-71. doi: 10.1086/314909.
10
Investigation of drug resistance against protease, reverse transcriptase, and integrase inhibitors by next-generation sequencing in HIV-positive patients.
J Med Virol. 2021 Jun;93(6):3627-3633. doi: 10.1002/jmv.26582. Epub 2020 Oct 30.
引用本文的文献
1
Multidrug-resistant HIV viral rebound during early syphilis: a case report.
BMC Infect Dis. 2020 Apr 7;20(1):273. doi: 10.1186/s12879-020-04999-4.
2
Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study.
PLoS One. 2019 Jul 3;14(7):e0218649. doi: 10.1371/journal.pone.0218649. eCollection 2019.
3
Crippling HIV one mutation at a time.
J Exp Med. 2008 May 12;205(5):1003-7. doi: 10.1084/jem.20080569. Epub 2008 May 5.
本文引用的文献
1
Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response.
AIDS. 2003 Feb 14;17(3):361-70. doi: 10.1097/00002030-200302140-00010.
2
Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.
AIDS. 2001 Nov 9;15(16):2189-91. doi: 10.1097/00002030-200111090-00016.
3
Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy.
AIDS. 2001 Jul 27;15(11):1359-68. doi: 10.1097/00002030-200107270-00005.
4
AIDS. Boosting immunity to HIV--can the virus help?
Science. 2000 Nov 3;290(5493):946-9. doi: 10.1126/science.290.5493.946.
5
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
N Engl J Med. 2001 Feb 15;344(7):472-80. doi: 10.1056/NEJM200102153440702.
6
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.
AIDS. 2000 Dec 22;14(18):2857-67. doi: 10.1097/00002030-200012220-00007.
7
Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.
AIDS. 2000 Oct 20;14(15):2247-55. doi: 10.1097/00002030-200010200-00005.
8
Immune control of HIV-1 after early treatment of acute infection.
Nature. 2000 Sep 28;407(6803):523-6. doi: 10.1038/35035103.
9
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.
AIDS. 1999 Dec 24;13(18):F123-7.
10
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
J Clin Invest. 1999 Sep;104(6):R13-8. doi: 10.1172/JCI7371.
Zotero 插件